Intravitreal triamcinolone as an adjunct to standard laser therapy in coexisting high-risk proliferative diabetic retinopathy and clinically significant macular edema

Retina

Volumn 30, Issue 2, 2010, Pages 254-259

  Mirshahi, Ahmad ^a   Shenazandi, Hamideh ^a   Lashay, Alireza ^a   Faghihi, Hushang ^a   Alimahmoudi, Asoo ^a   Dianat, Seyedsaeid ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Clinically significant macular edema; Panretinal photocoagulation; Proliferative diabetic retinopathy; Triamcinolone acetonide

Indexed keywords

TRIAMCINOLONE ACETONIDE;

ADJUVANT THERAPY; ADULT; ARTICLE; CATARACT; CATARACT EXTRACTION; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DIABETIC RETINOPATHY; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HIGH RISK PATIENT; HUMAN; INTRAOCULAR PRESSURE; LASER COAGULATION; MACULAR PHOTOCOAGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OPTICAL RESOLUTION; PANRETINAL PHOTOCOAGULATION; RANDOMIZED CONTROLLED TRIAL; RETINA DETACHMENT; RETINA MACULA EDEMA; RETINA MACULA LUTEA; THERAPY EFFECT; THICKNESS; VISUAL ACUITY; VITRECTOMY; VITREOUS HEMORRHAGE;

CHEMOTHERAPY, ADJUVANT; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; INJECTIONS; INTRAOCULAR PRESSURE; LASER COAGULATION; MACULAR EDEMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETINA; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; TRIAMCINOLONE ACETONIDE; VISUAL ACUITY; VITREOUS BODY;

EID: 76749136263     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181b4f125     Document Type: Article

References (20)

1. Porta M, Bandello F. Diabetic retinopathy: a clinical update. Diabetologia 2002;45:1617-1634.
2. Shimura M, Yasuda K, Nakazaya T, et al. Quantifying alterations of macular thickness before and after pan-retinal photocoagulation in patients with severe diabetic retinopathy and good vision. Ophthalmology 2003;110:2386-2394.
3. Brooks HL, Caballero S, Newell CK, et al. Vitreous levels of vascular endothelial growth factor and stromalderived factor 1 in patients with diabetic retinopathy and cystoid macular edema before and after intraocular injection of triamcinolone. Arch Ophthalmol 2004;122:1801-1807.
4. Avci R, Kaderli B. Intravitreal triamcinolone injection for chronic diabetic macular oedema with severe hard exudates. Graefes Arch Clin Exp Ophthalmol 2006;244:28-35. (Pubitemid 43013179)
5. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002;109:920-927.
6. Massin P, Audren F, Haouchine B, et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema. Ophthalmology 2004;111:218-225.
7. Chan A, Duker JS. A standardized method for reporting changes in macular thickening using optical coherence tomography. Arch Ophthalmol 2005;123:939-943.
8. Wilson CA, Berkowitz BA, Sato Y, et al. Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation. Arch Ophthalmol 1992;110: 1155-1159.
9. Scholes GN, O'Brien WJ, Abrams GW, Kubicek MF. Clearance of triamcinolone from vitreous. Arch Ophthalmol 1985; 103:1567-1569.
10. Jonas JB, Sofker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol 2001;132:425-427. (Pubitemid 32768624)
11. Zacks DN, Johnson MW. Combined intravitreal injection of triamcinolone acetonide and panretinal photocoagulation for coexisting diabetic macular edema and proliferative diabetic retinopathy. Retina 2005;25:135-140.
12. Zein WM, Noureddin BN, Jurdi FA, et al. Panretinal photocoagulation and intravitreal triamcinolone acetonide for the management of proliferative diabetic retinopathy with macular edema. Retina 2006;26:137-142.
13. Sutter FK, Simpson JM, Gillies MC. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment. Three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology 2004;111:2044-2049.
14. Gillies MC, Sutter FK, Simpson JM, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 2006;113:1533-1538.
15. Avitabile T, Longo A, Reibaldi A. Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. Am J Ophthalmol 2005; 140:695-702.
16. Kang SW, Sa HS, Cho HY, Kim JI. Macular grid photocoagulation after intravitreal triamcinolone acetonide for diffuse diabetic macular edema. Arch Ophthalmol 2006;124: 653-658.
17. Bandello F, Polito A, Pognuz DR, et al. Triamcinolone as Adjunctive Treatment to Laser Panretinal Photocoagulation for Proliferative Diabetic Retinopathy. Arch Ophthalmol 2006;124:643-650.
18. Margolis R, Singh RP, Bhatnagar P, Kaiser PK. Intravitreal triamcinolone as adjunctive treatment to laser panretinal photocoagulation for concomitant proliferative diabetic retinopathy and clinically significant macular oedema. Acta Ophthalmol 2008;86:105-110.
19. Kaderli B, Avci R, Gelisken O, et al. Intravitreal triamcinolone as an adjunct in the treatment of concomitant proliferative diabetic retinopathy and diffuse diabetic macular oedema. Combined IVTA and laser treatment for PDR with CSMO. Int Ophthalmol 2005;26:207-214.
20. Diabetic Retinopathy Clinical Research Network. A Randomized Trial Comparing Intravitreal Triamcinolone Acetonide and Focal/Grid Photocoagulation for Diabetic Macular Edema. Ophthalmology 2008;115:1447-1459.